Insulin Efsitora Alfa (Onswik)

Insulin efsitora alfa is Eli Lilly's answer to Novo Nordisk's once-weekly insulin icodec — a weekly basal insulin built through a completely different engineering route (an antibody-Fc fusion, not albumin binding), backed by its own five-trial Phase 3 program (QWINT), all now published. The EU's CHMP recommended approval (as Onswik) in June 2026, but formal European Commission authorization and a US FDA decision both remained pending as of this review. Like icodec, its dedicated type 1 diabetes trial found a real, statistically significant increase in hypoglycemia against a daily comparator — the same tradeoff this site's insulin icodec page already flags for its own once-weekly rival.

A different way to build a once-weekly insulin

Ordinary insulin is cleared from the body within hours, which is why basal insulin has traditionally meant a daily injection — a problem this site's insulin icodec page already covers in detail for Novo Nordisk's once-weekly entry. Eli Lilly's insulin efsitora alfa (LY3209590) reaches the same once-weekly goal through a structurally different route. Rather than icodec's fatty-acid side chain that binds reversibly to circulating albumin, efsitora alfa is a novel single-chain insulin variant genetically fused, via a linker, to the Fc (fragment crystallizable) region of a human IgG2 antibody — the same general fusion-protein engineering trick this site's efbemalenograstim alfa page describes for a completely different hormone. The Fc fusion slows the molecule's clearance and cellular uptake, extending its half-life to roughly 17 days in preclinical and clinical pharmacology studies. That's long enough not just for once-weekly dosing, but for an unusually flat pharmacokinetic profile: a reported peak-to-trough concentration ratio of about 1.14, meaning circulating insulin levels vary by well under 15% across the week, in contrast to the more front-loaded exposure curve icodec's own page describes.

The QWINT program: five trials, one basal insulin

Efsitora alfa's Phase 3 evidence comes from the QWINT program, five separate randomized, active-controlled trials covering different patient populations. QWINT-1 (Rosenstock J, Bailey T, Connery L, et al., for the QWINT-1 Trial Investigators, "Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy," N Engl J Med 2025;393:325-335, PMID 40548694, DOI: 10.1056/NEJMoa2502796) tested a simplified, largely fixed-dose regimen against daily glargine in insulin-naive adults with type 2 diabetes, finding noninferior HbA1c reduction. QWINT-2 (Wysham C, Bajaj HS, Del Prato S, et al., for the QWINT-2 Investigators, "Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment," N Engl J Med 2024;391:2201-2211, PMID 39254740, DOI: 10.1056/NEJMoa2403953) used a more conventional treat-to-target titration against daily degludec in a similar insulin-naive population, also meeting noninferiority — reducing HbA1c by 1.34 percentage points versus 1.26 for degludec over 52 weeks. QWINT-3 and QWINT-4 extended the comparison to adults already using daily basal insulin, and basal-plus-mealtime (basal-bolus) regimens respectively, both against degludec or glargine, with efsitora again meeting noninferiority on HbA1c. Across all four type 2 diabetes trials, hypoglycemia and other safety measures came out broadly similar to the daily comparators — the meaningful exception was the program's fifth trial, run specifically in type 1 diabetes.

The same type 1 diabetes hypoglycemia signal as icodec

QWINT-5 (Bergenstal RM, Weinstock RS, Mathieu C, et al., "Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial," Lancet 2024;404(10458):1132-1142, DOI: 10.1016/S0140-6736(24)01804-X) randomized 692 adults with type 1 diabetes, each also using mealtime insulin lispro, to weekly efsitora or daily degludec over 52 weeks. Efsitora met its primary noninferiority endpoint on HbA1c reduction. But combined level 2 (blood glucose under 54 mg/dL) or level 3 (severe) hypoglycemia occurred at a real, statistically higher rate with efsitora than degludec — 14.03 versus 11.59 events per patient-year of exposure, an estimated rate ratio of 1.21 (95% CI 1.04-1.41, p=0.016) — with the gap widest in the first 12 weeks of treatment.

Regulatory status: ahead in some ways, behind in others

As of this review, insulin efsitora alfa is not yet approved anywhere. The EU's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 25 June 2026, recommending marketing authorization (as Onswik) for type 2 diabetes — but the European Commission's own formal authorization, the step that actually confirms an EU-wide approval, remained pending as of August 2026, weeks after the CHMP vote. In the UK, the National Institute for Health and Care Excellence (NICE) issued final draft guidance in August 2026 backing NHS funding for Onswik in England and Wales, ahead of and contingent on the MHRA's own separate marketing approval. In the US, Eli Lilly has said it intended to file with regulators by the end of 2025; as of this review, no FDA approval, rejection or Complete Response Letter had been publicly confirmed. That leaves both once-weekly insulins on this site (icodec and efsitora alfa) in an unusual position: icodec now holds a US approval but reached other major markets roughly two years earlier, while efsitora alfa is closer to a first EU authorization but has yet to clear either the EU's or the US's final regulatory step.

What this adds to the site's weekly-insulin comparison

Between insulin icodec and insulin efsitora alfa, this site now covers both real engineering approaches to once-weekly basal insulin dosing that have reached late-stage regulatory review: reversible albumin binding via a fatty-diacid side chain (icodec), and an antibody Fc-fusion protein (efsitora alfa) — the same fusion-protein principle already covered here through a different hormone, efbemalenograstim alfa. Both drugs solve the same clinical problem, both show a real, replicated hypoglycemia signal specifically in type 1 diabetes populations, and both illustrate how a hormone that's dosed based on tight, immediate physiological feedback creates sharper safety tradeoffs than the once-weekly peptide hormones (like somapacitan, this site's once-weekly growth hormone) that don't carry the same acute hypoglycemia risk. This page will be updated once either regulator reaches a final decision.